Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers

AIDS

Volumn 27, Issue 4, 2013, Pages 519-528

  French, Martyn A ^a,b   Center, Rob J ^c   Wilson, Kim M ^d   Fleyfel, Ibrahim ^a   Fernandez, Sonia ^a   Schorcht, Anna ^c   Stratov, Ivan ^c   Kramski, Marit ^c   Kent, Stephen J ^c   Kelleher, Anthony D ^e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d NRL   (Australia)

^e St Vincent's Centre for Applied Medical Research   (Australia)

Author keywords

antibody dependent cell mediated cytotoxicity; controllers; HIV; immune complexes002Aimmunoglobulin G2 antibodies

Indexed keywords

CASPASE 3; ENVELOPE PROTEIN; FC RECEPTOR IIA; GAG PROTEIN; GLYCOPROTEIN GP 140; HLA B ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; PROTEIN P51; PROTEIN P55; PROTEIN P66; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS ENVELOPE; VIRUS REPLICATION; WESTERN BLOTTING;

ADAPTIVE IMMUNITY; ALLELES; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV SEROPOSITIVITY; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; RECEPTORS, IGG; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 84873395169     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835cb720     Document Type: Article

References (60)

1. Sáez-Cirión A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gagspecific CD8 T cell responses. J Immunol 2009; 182:7828- 7837.
2. Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, Pollard RB, et al. Immunodominant HIV-specific CD8R T-cell responses are common to blood and gastrointestinal mucosa, and Gag-Specific responses dominate in rectal mucosa of HIV controllers. J Virol 2010; 84:10354-10365.
3. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008; 82:5398-5407.
4. International HIV Controllers Study Group. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-1557.
5. Migueles SA, Connors M. Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA 2010; 304:194-201.
6. Fadda L, Alter G. KIR/HLA: genetic clues for a role of NK cells in the control of HIV. Adv Exp Med Biol 2011; 780:27-36.
7. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, et al. Heterogeneous neutralizing antibody and antibodydependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23:897-906.
8. Chung AW, Isitman G, Navis M, Kramski M, Center RJ, Kent SJ, et al. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A 2011; 108:7505-7510.
9. Schmidt G, Amiraian K, Frey H, Wethers J, Stevens RW, Berns DS. Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24. J Clin Microbiol 1989; 27:843-848.
10. Fernandez-Cruz E, Desco M, Garcia Montes M, Longo N, Gonzalez B, Zabay JM. Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users. AIDS 1990; 4:987-994.
11. Mertens T, Ramon A, Kruppenbacher JP, Heitmann K, Pika U, Leyssens N, et al. Virological examinations of patients with AIDS-related complex/Walter-Reed 5 enrolled in a doubleblind placebo-controlled study with intravenous gammaglobulin administration. Prognostic value of antip24 determination. The ARC-IVIG Study Group. Vox Sang 1990; 59 (Suppl 1): 21-29.
12. Allain JP, Laurian Y, Einstein MH, Braun BP, Delaney SR, Stephens JE, et al. Monitoring of specific antibodies to human immunodeficiency virus structural proteins: clinical significance. Blood 1991; 77:1118-1123.
13. Cheingsong-Popov R, Panagiotidi C, Bowcock S, Aronstam A, Wadsworth J, Weber J. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ 1991; 302:23-26.
14. Sheppard HW, Ascher MS, McRae B, Anderson RE, Lang W, Allain JP. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr 1991; 4:704-712.
15. Farzadegan H, Chmiel JS, Odaka N, Ward L, Poggensee L, Saah A, et al. Association of antibody to human immunodeficiency virus type 1 core protein (p24), CD4R lymphocyte number, and AIDS-free time. J Infect Dis 1992; 166:1217-1222.
16. Chargelegue D, Colvin BT, Ótoole CM. A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: immunoglobulin G titre and avidity are early predictors of clinical course. AIDS 1993; 7 (Suppl 2): S87-S90.
17. Chargelegue D, Ótoole CM, Colvin BT. A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1R patients with haemophilia: titre and avidity. Clin Exp Immunol 1993; 93:331-336.
18. Zwart G, van der Hoek L, Valk M, Cornelissen MT, Baan E, Dekker J, et al. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Virology 1994; 201:285-293.
19. Morand-Joubert L, Bludau H, Lerable J, Petit JC, Lefre JJ. Serum antip24 antibody concentration has a predictive value on the decrease of CD4 lymphocyte count higher than aciddissociated p24 antigen. J Med Virol 1995; 47:87-91.
20. Hogervorst E, Jurriaans S, de Wolf F, van Wijk A, Wiersma A, Valk M, et al. Predictors for non and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24- specific but not V3-specific antibody levels. J Infect Dis 1995; 171:811-821.
21. Chargelegue D, Stanley CM, Ótoole CM, Colvin BT, Steward MW. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin Exp Immunol 1995; 99:175-181.
22. Garland FC, Garland CF, Gorham ED, Brodine SK. Western blot banding patterns of HIV rapid progressors in the U.S. Navy Seropositive Cohort: implications for vaccine development. Navy Retroviral Working Group. Ann Epidemiol 1996; 6: 341-347.
23. Thomas HI, Wilson S, Ótoole CM, Lister CM, Saeed AM, Watkins RP, et al. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clin Exp Immunol 1996; 103:185-191.
24. Mofenson LM, Harris DR, Rich K, Meyer WA 3rd, Read JS, Moye J Jr, et al. Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1- infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. AIDS 1999; 13: 31-39.
25. Read JS, Rich KC, Korelitz JJ, Mofenson LM, Harris R, Moye JH Jr, et al. Quantification of human immunodeficiency virus type 1 p24 antigen and antibody rivals human immunodeficiency virus type 1 RNA and CD4R enumeration for prognosis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Pediatr Infect Dis J 2000; 19:544-551.
26. Binley JM, Klasse PJ, Cao Y, Jones I, Markowitz M, Ho DD, et al. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 1997; 71:2799-2809.
27. Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynart M, Sicard D, et al. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of longterm nonprogression. AIDS Res Hum Retroviruses 2001; 17:1435-1446.
28. French MA, Tanaskovic S, Law MG, Lim A, Fernandez S, Ward LD, et al. Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcgammaRIIa genotype. AIDS 2010; 24:1983-1990.
29. Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, et al. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses 2010; 26:445-458.
30. Pan-Hammarstrom Q, Zhao Y, Hammarstrom L. Class switch recombination: a comparison between mouse and human. Adv Immunol 2007; 93:1-61.
31. Yoo EM, Wims LA, Chan LA, Morrison SL. Human IgG2 can form covalent dimers. J Immunol 2003; 170:3134-3138.
32. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113:3716-3725.
33. Shashidharamurthy R, Zhang F, Amano A, Kamat A, Panchanathan R, Ezekwudo D, et al. Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A. J Immunol 2009; 183:8216-8224.
34. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47.
35. Rodriguez ME, van der Pol WL, Sanders LA, van de Winkel JG. Crucial role of FcgammaRIIa (CD32) in assessment of functional anti-Streptococcus pneumonia antibody activity in human sera. J Infect Dis 1999; 179:423-433.
36. Lovgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Ro?nnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjo?gren's syndrome autoantigenassociated RNA. Arthritis Rheum 2006; 54:1917-1927.
37. Dugast AS, Tonelli A, Berger CT, Ackerman ME, Sciaranghella G, Liu Q, et al. Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 2011; 415:160-167.
38. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 2010; 1183:89-103.
39. Stahl D, Sibrowski W. IgG2 containing IgM-IgG immune complexes predominate in normal human plasma, but not in plasma of patients with warm autoimmune haemolytic anaemia. Eur J Haematol 2006; 77:191-202.
40. Xu W, Santini PA, Sullivan JS, He B, Shan M, Ball SC, et al. HIV- 1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 2009; 10:1008-1017.
41. Wilson KM, Johnson EI, Croom HA, Richards KM, Doughty L, Cunningham PH, et al. Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS 2004; 18:2253-2259.
42. Wren L, Parsons S, Isitman G, Center RJ, Kelleher AD, Stratov I, et al. Influence of cytokines on HIV-specific antibodydependent cellular cytotoxicity activation profile of natural killer cells. PloS One 2012; 7:e38580.
43. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol 2009; 182:1202-1210.
44. Chung AW, Navis M, Isitman G, Wren L, Silvers J, Amin J, et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 2011; 58:127-131.
45. Tomaras GD, Haynes BF. HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS 2009; 4:373-379.
46. Kosmrlj A, Read EL, Qi Y, Allen TM, Altfeld M, Deeks SG, et al. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 2010; 465:350- 354.
47. Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. Pol as a target for Antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 2011; 412:110-116.
48. Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125:S41-S52.
49. Forthal DN, Landucci G, Ding H, Kappes JC, Wang A, Thung I, et al. IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS 2011; 25:2099-2104.
50. Giha HA, Nasr A, Iriemenam NC, Balogun HA, Arnot D, Theander TG, et al. Age-dependent association between IgG2 and IgG3 subclasses to Pf332-C231 antigen and protection from malaria, and induction of protective antibodies by sub-patent malaria infections, in Daraweesh. Vaccine 2010; 28:1732-1739.
51. Allhorn M, Olin AI, Nimmerjahn F, Collin M. Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS One 2008; 3:e1413.
52. Moore JS, Wu X, Kulhavy R, Tomana M, Novak J, Moldoveanu Z, et al. Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS 2005; 19:381-389.
53. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115:407-417.
54. Wang JP, Asher DR, Chan M, Kurt-Jones EA, Finberg RW. Cutting edge: antibody-mediated TLR7-dependent recognition of viral RNA. J Immunol 2007; 178:3363-3367.
55. Liu P, Overman RG, Yates NL, Alam SM, Vandergrift N, Chen Y, et al. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol 2011; 85:11196-11207.
56. Nishanian P, Huskins KR, Stehn S, Detels R, Fahey JL. A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIVinfected individuals. J Infect Dis 1990; 162:21-28.
57. Dianzani F, Antonelli G, Riva E, Turriziani O, Antonelli L, Tyring et al. Is human immunodeficiency virus RNA load composed of neutralized immune complexes? J Infect Dis 2002; 185:1051-1054.
58. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 2010; 10:712-722.
59. Lind A, Sommerfelt M, Holmberg JO, Baksaas I, Sørensen B, Kvale D. Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 R and CD8 R T cell responses lasting more than seven years. Scand J Infect Dis 2012; 44:566-572.
60. Coleman JK, Pu R, Martin M, Sato E, Yamamoto JK. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection. AIDS 2005; 19:1457-1466.